AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01852539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
Study NCT03316014 — intervention group
Intervention type: OTHER
Intervention: Adverse drug reaction
Description: description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
Study NCT02901210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified delorme procedure
Study NCT02256124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Study NCT02256124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01509560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16
Study NCT04625881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple derived fiber
Description: This is a combination of soluble and insoluble fiber
Study NCT04625881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Apple derived fiber
Description: This is a combination of soluble and insoluble fiber
Study NCT03576963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT03576963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03046589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP13
Description: dose escalation
Study NCT03046589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: control to dose-escalation
Study NCT02123589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedation(midazolam and fentanyl )
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
Study NCT02123589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep and daily interruption of sedation(midazolam and fentanyl )
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
Study NCT02123589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light sedation(midazolam and fentanyl )
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (Certican)
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Certican)
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (Neoral)
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Neoral)
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab (Simulect)
Study NCT01852539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol 2.0 mg/kg was administrated
Study NCT01852539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway (LMA)
Description: The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
Study NCT02372201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydro Colon Therapy plus probiotic
Description: Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
Study NCT02250612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 0.375% SYL040012 (bamosiran)
Study NCT00154284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect)
Study NCT03040778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
Study NCT02256488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc_LOT A
Description: Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
Study NCT02256488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc_LOT B
Description: Single IM administration dose of 0.5 mL of TIVc
Study NCT02256488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVc_LOT C
Description: Single IM administration dose of 0.5 mL of TIVc
Study NCT02256488 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVf
Description: Single IM administration dose of 0.5 mL of TIVf
Study NCT05740371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Argatroban
Description: Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT > 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible.
Study NCT02502721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20151
Study NCT02502721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20152
Study NCT03040778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT03040778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
Study NCT03714074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK implant abutment
Description: Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure
Study NCT03714074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia abutment
Description: Imolants will be restored with zirconia abutments and a PEEK superstructure
Study NCT02250612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 0.750% SYL040012 (bamosiran)
Study NCT03464331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero-time exercises
Description: The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
Study NCT03464331 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: relaxation exercises and deep-breathing exercises
Description: The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
Study NCT02250612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 1.125% SYL040012 (bamosiran)
Study NCT02250612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 drop of 1.5% SYL040012 (bamosiran)
Study NCT02250612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 drop of 0.5 % timolol maleate
Study NCT00773968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: 120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
Study NCT03112382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc supplement plus vitamin A and E
Study NCT03112382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A and E
Study NCT02492100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modality sexual dysfunction intervention
Study NCT02430519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Furcation treatment with PRF
Description: PRF Placed into the furcation after flap elevation and debridement
Study NCT02430519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Furcation Treatment with Allograft and GTR
Description: Allograft and GTR placed into furcation after flap elevation and debridement
Study NCT03377491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
Study NCT02430519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)
Study NCT02430519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich fibrin
Study NCT02754271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit for Dialysis
Description: A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
Study NCT00649922 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adalimumab
Description: 80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
Study NCT00649922 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 injections Day 1, 1 injection Days 15 and 29
Study NCT03377491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
Study NCT03377491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
Study NCT03377491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
Study NCT03377491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
Study NCT01801020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: temperature measuremts
Description: temporal artery temperature measurements will be taken from the forehead
Study NCT00649922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg adalimumab every other week
Study NCT03223415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection and isolation of C. difficile carriers
Description: Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward.
Study NCT02954133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (7 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
Study NCT02954133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (5 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
Study NCT01801020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: temperature measuremts
Description: different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
Study NCT03902704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleverscope
Description: the device is used in patients without difficult airways predictors
Study NCT03902704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope / Videolaryngoscope C-MAC® Storz
Description: the device is used in patients with difficult airways predictors
Study NCT02274714 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Only
Description: Subjects will have an interview with a study coordinator to fill out questionnaires for the study
Study NCT04293146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre-pectoral IBBR
Description: The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
Study NCT04293146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sub-pectoral IBBR
Description: The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
Study NCT00668122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: Ciprofloxacin XR 1000 mg orally once a day
Study NCT00668122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro IR (Ciprofloxacin, BAYQ3939)
Description: Ciprofloxacin IR 500 mg orally twice a day
Study NCT02925455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralaterally-controlled functional electrical stimulation
Description: Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
Study NCT02925455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand therapy video games
Description: Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
Study NCT02925455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand therapy video games
Description: Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
Study NCT03484975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Observation group
Description: Collect coronary images with a hybrid IVUS OCT system.
Study NCT01843426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan
Description: An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
Study NCT04477642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: 10mg/kg intravenously administered on Day 1
Study NCT02403726 — intervention group
Intervention type: PROCEDURE
Intervention: Operation
Description: Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
Study NCT02403726 — intervention group
Intervention type: PROCEDURE
Intervention: Non-operative treatment
Description: Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
Study NCT01754662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 2 bars daily for 8 weeks.
Study NCT01754662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavones
Description: 2 bars daily for 8 weeks.
Study NCT02954133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse
Description: Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
Study NCT01754662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: 2 bars daily for 8 weeks.
Study NCT02954133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign (3.5 day)
Description: Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
Study NCT01754662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03093922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg/m\^2
Study NCT03093922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2
Study NCT03093922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m\^2
Study NCT02278094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Muscle Trainer (TMT)
Description: Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
Study NCT02278094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory Muscle Trainer (TIMT)
Description: Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
Study NCT02278094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.